PAHC
Phibro Animal Health Corp-A
NASDAQ · Pharmaceuticals
$53.07
+3.07 (+6.14%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 1.29B | 1.16B | 1.25B | 1.31B | 972.76M |
| Net Income | 48.15M | 38.97M | 377.93M | 335.32M | 253.19M |
| EPS | — | — | — | — | — |
| Profit Margin | 3.7% | 3.5% | 30.2% | 25.7% | 26.0% |
| Rev Growth | +11.2% | +11.2% | +13.2% | +2.9% | -6.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 770.60M | 770.60M | 382.40M | 399.08M | 413.63M |
| Total Equity | 306.32M | 306.32M | 1.10B | 1.04B | 1.11B |
| D/E Ratio | 2.52 | 2.52 | 0.35 | 0.38 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 155.71M | 133.01M | 451.24M | 482.41M | 394.81M |
| Free Cash Flow | — | — | 182.99M | 282.39M | 183.99M |